NCT06566248 - A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 20, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

March 31, 2025

Conditions

Chronic Hepatitis B

Interventions

DRUG

TQA3810 tablets+NUC

TQA3810 is a novel, effective and highly selective small-molecule oral Toll-like receptors-8 agonist.

DRUG

Placebo+NUC

"NUC:~Entecavir Dispersible Tablets, Inhibit viral replication; Tenofovir Disoproxil Fumarate Tablets, Nucleotide reverse transcriptase inhibitors; Tenofovir Alafenamide Fumarate Tablets, Inhibit HBV replication."

Trial Locations (6)

110000

NOT_YET_RECRUITING

Shenyang Sixth People's Hospital, Shenyang

210031

NOT_YET_RECRUITING

Nanjing Drum Tower Hospital, Nanjing

215131

NOT_YET_RECRUITING

The Fifth People's Hospital of Suzhou, Suzhou

563000

NOT_YET_RECRUITING

Zunyi Medical University Affiliated Hospital, Zunyi

710061

RECRUITING

The First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an

733099

NOT_YET_RECRUITING

Gansu Wuwei Tumour Hospital, Wuwei